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Resident peritoneal macrophages from morphine-addicted rats (4 days) released more prostaglandin (PG) 
E, and thromboxane (TX) B2, but not 6-keto-PGFt,, than cells from control animals. This effect, which was 
due to an enhancement of endogenous AA turnover, was not related to any changes in CAMP synthesis 
or lysososomal enzyme secretion. [D-A1aZ]-Met-enkephalin had no effect on eicosanoid release in vitro. Both 
morphine and PGE, have been shown to depress macrophage functions. We suggest hat morphine-stimu- 
lated macrophage PGE, synthesis, and the consequent inhibition of phagocytosis, could contribute to the 
decreased resistance to infections associated with opiate addiction. 
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1. INTRODUCTION 
It is known that morphine addicts have an 
enhanced risk of infection and reduced capacity to 
combat disease. This has been mainly ascribed to 
malnutrition, shared needles, toxic impurities in 
the drugs and other non-hygienic procedures which 
could account for the generally poor state of health 
and low resistance to disease of this group [ 11. 
However, morphine has been shown to reduce the 
survival time of animals with bacteria1 and fungal 
infections indicating that some specific action of 
morphine is involved [2]. The same authors also 
found that macrophage phagocytosis, which plays 
an important role in protecting against extra- 
cellular pathogens, is reduced by morphine. 
Enkephalins and endorphins, on the other hand, 
appear to stimulate macrophage functions, for ex- 
ample, chemotaxis, chemiluminescence, antibody- 
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dependent cytotoxicity and superoxide generation 
[3-61. Further, spleen macrophages have been 
reported to synthesise y-endorphine [7]. These 
data indicate that opiates and endogenous opioid 
peptides could modify macrophage functions in 
vivo. PGE2, a cyclooxygenase metabolite of AA, is 
an important regulator of macrophage functions 
inhibiting, amongst others, chemiluminescence, 
lysosomal enzyme release and, importantly, 
phagocytosis [S-lo]. It is possible therefore that 
morphine could suppress the immune response by 
stimulating macrophage PGEz synthesis and 
opioid peptides could stimulate the immune 
response by inhibiting it. In order to clarify these 
possibilities we have investigated the effect of mor- 
phine dependence on resident rat peritoneal 
macrophage cyclooxygenase metabolite release 
and its modification by [D-Ala*]-Met-enkephalin. 
2. MATERIALS AND METHODS 
Male Wistar rats (175-200 g) were bought from 
the Central Laboratory Animal House, Zeist. An- 
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tisera against PGEz and TxB2 were obtained from quired concentration (final ethanol concentration 
the Institute Pasteur, Paris, and antisera against 0.001%) and naloxone hydrochloride and enke- 
6-keto-PGFra from Seragen (Boston, USA). Stan- phalin were dissolved in GBSS. 10 ~1 volumes were 
dard compounds, eicosanoids, AA and CAMP then added to 1 ml of the cell suspension at the 
were ordered from Sigma and standard radio- beginning of the incubation. In some experiments, 
labelled compounds from New England Nuclear. to investigate the effect of enkephalin, macro- 
[D-Ala2]-Met-enkephalin (enkephalin) was bought phages were isolated and used 24 h after injecting 
from Peninsula Laboratories (Belmont, CA). 5 ml of a 1% starch suspension intraperitoneally. 
Pellets, control or morphine-impregnated 
(5 x 75 mg pellets/rat, 35 mg morphine/pellet), 
were implanted subcutaneously in the backs of rats 
under light ether anaesthesia [1 11. After 4 days the 
resident peritoneal macrophages were isolated 
from Geys balanced salt solution (GBSS) washes 
of rat peritonea, by density gradient centrifugation 
over Ficoll, and suspended at 1 x lo6 viable 
cells/ml GBSS. The macrophage preparation was 
greater than 85% pure and greater than 95% 
viable, as assessed by trypan blue exclusion. Ali- 
quots (1 ml) were added to Plastibrand poly- 
propylene reaction vials and incubated for 1 h at 
37°C in a water bath. The cells were then cen- 
trifuged down and the medium stored at -70°C 
for later analysis of PGE2, TxB2, 6-keto-PGFra, 
lactate dehydrogenase (LDH) and /3-glucuronidase 
(GUR). LDH was assayed by the method of 
Wroblewsky and LaDue [12], and GUR activity 
was quantified using the conversion of phenol- 
phthalein glucuronic acid to phenolphthalein, 
which was then measured spectrophotometrically 
(555 nm). 
3. RESULTS 
The effect of morphine ex vivo was investigated 
in 3 separate experiments. For each experiment 
macrophages were pooled from 5 control and 5 
morphine rats. The in vitro experiments were per- 
formed twice. Results given are typical of the other 
experiments performed. Student’s t-test was used 
to assess ignificance. 
The cell pellet was heated for 5 min at 95°C in 
150 ~1 Tris-EDTA buffer and the medium CAMP 
assayed using a protein binding method [13]. 
When used, AA (stored as an ethanolic solution 
under nitrogen) was diluted with GBSS to the re- 
Resident macrophages isolated from peritonea 
of morphine-treated rats released more PGE2 and 
TxB2, but not 6-keto-PGFr,, than cells isolated 
from control animals. No differences in eicosanoid 
formation were observed when the macrophages 
were incubated with exogenous AA (table 1). As 
changes in PGE2 and TxB2 were parallel we decid- 
ed to assay only TxB2 in the following experiments. 
No changes in basal or AA-stimulated TxB2 syn- 
thesis were found when morphine or control 
macrophages were incubated in vitro with either 
naloxone or enkephalin (table 2). Enkephalin 
(lO-8-lO-4 M) had no consistent effect on the 
basal synthesis of TxB2 and CAMP and secretion of 
GUR by resident peritoneal macrophages. Similar- 
ly, AA- and carrageenin-stimulated TxB2 forma- 
tion was also unaffected (not shown). 
Enkephalin (10-8-10-4 M) was also without ef- 
Table 1 
Effect of morphine (ex vivo) on basal and arachidonic acid-stimulated release 
of PGE2, TxB2 and 6-keto-PGFr, from resident rat peritoneal macrophages 
Treatment PGE2 TxB2 6-Keto-PGF,, 
Control 0.88 + 0.06 4.80 f 1.14 23.60 + 3.60 
Morphine 2.13 f 0.35” 9.80 + 0.35” 25.30 z!z 0.90 
Control + AA 27.30 f 2.30 31.00 f 1.73 137.5 + 10.6 
Morphine + AA 26.30 + 1.50 43.00 + 11.0 146.7 + 20.0 
“Significantly different (P< 0.01) from control values 
Results (ng/ml) are means + SD of triplicate incubations. AA concentration 
was 1 pg/ml 
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Table 2 
Effect of naloxone and enkephalin (in vitro) on basal and ar- 
chidonic acid-stimulated TxB2 synthesis using resident rat 
peritoneal macrophages from morphine-treated and control rats 
Treatment TxBz(ng/ml) 
Control Morphine 
Control 5.92 k 1.13 8.00 f 0.53a 
+ naloxone 7.00 + 0.50 9.75 f 1.30a 
+ enkephalin 6.92 z!z 1.18 9.42 rf: 2.24 
Naloxone + 
enkephalin 6.00 + 0.87 8.77 & 1.25a 
Control + AA 19.83 & 1.26 18.90 f 2.95 
Naloxone + AA 20.33 + 1.60 19.67 + 2.90 
Enkephalin + AA 17.83 f 2.84 19.33 + 1.89 
Naloxone + 
enkephalin + AA 20.50 f 1.32 21.80 + 3.00 
“Significantly different (P< 0.01) from control values 
Results are means f SD of triplicate incubations. Naloxone con- 
centration was 10m6 M and enkephalin concentration, lo-* M. AA 
concentration was 1 pg/ml 
Table 3 
Effect of enkephalin on TXBZ and CAMP synthesis and the release of p- 
glucuronidase from 24 h starch-elicited rat peritoneal macrophages 
Enkephalin(M) TxBz(ng/ml) CUR (mu) CAMP (pmol) 
Control 0.28 it_ 0.03 0.060 +_ 0.004 4.74 f 0.1 
1o-4 0.26 + 0.04 0.064 * 0.003 7.50 f 2.0a 
10-6 0.27 f 0.05 0.062 + 0.002 5.45 f 0.5a 
10-s 0.25 + 0.04 0.063 + 0.002 4.30 f 1.0 
“Significantly different from control value (P<O.Ol) 
Results are means + SD of triplicate incubations 
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feet on the basal synthesis of TxB2 and the release 
of CUR from 24 h starch-elicited peritoneal 
macrophages. However, there was a dose-response 
stimulation of CAMP synthesis (table 3). 
4. DISCUSSION 
The basal release of eicosanoids is linear over a 
1 h incubation period (unpublished) and chronic 
morphine dependence enhanced this synthesis. 
AA-stimulated release of PGEz and TxB2 from 
resident peritoneal macrophages was not affected 
however (AA-stimulated eicosanoid release is not 
saturated at 1 fig/ml AA; unpublished). That is, 
morphine had no effect on cyclooxygenase activity 
8 
directly but enhanced AA availability. Unlike 
many mediators, PGs are not thought to be stored 
intracellularly. Thus synthesis is synonymous with 
release. 
A small inflammatory reaction was initiated by 
implantation of the pellets. We are unable to say, 
therefore, whether the morphine effect was direct, 
i.e. an interaction between morphine and macro- 
phages, or indirect, i.e. morphine modulated the 
inflammation or acted via central opioid receptors. 
The finding that morphine treatment had no effect 
on either CAMP levels or CUR secretion indicates 
that morphine did not stimulate macrophage func- 
tions in general. Morphine has been reported to 
alter the body’s defence system by decreasing the 
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number of circulating polymorphonuclear 
leukocytes and inhibiting macrophage phago- 
cytosis [2]. The mechanism by which morphine 
modifies this macrophage function is not known 
but our results indicate a possible mechanism. 
PGE2 has been shown in a number of models to be 
anti-inflammatory, for example it inhibits 
carrageenin-induced granuloma formation [ 151. It 
also specifically inhibits oxygen radical formation 
and macrophage phagocytosis [8,10]. PGE2 syn- 
thesises from exogenously added AA also inhibited 
carrageenin-induced granuloma formation [ 161. 
The latter finding is particularly interesting as it 
demonstrated that the anti-inflammatory action of 
PGE2 predominates although other cycloox- 
ygenase (e.g. TxB2) and lipoxygenase (e.g. LTs) 
metabolites are formed. PGE2 is, thus, a potent 
regulator of macrophage functions and it is feasi- 
ble that morphine could depress various aspects of 
the body’s defence system by stimulating PGE2 
synthesis. Collier et al. [17] have reported that 
morphine (3.5 x 10e4 M) and naloxone (2.8 
x low4 M) stimulate PGEz synthesis, from ex- 
ogenous AA, by bull seminal vesical homogenate. 
The stimulatory effect of morphine was not 
naloxone-sensitive. Similarly, naloxone did not in- 
hibit the increase in eicosanoid release observed by 
us using macrophages from dependent rats. Nalox- 
one (10m6 M), however, did not stimulate 
eicosanoid release in our experiments. We are now 
investigating the possibility that naloxone can 
stimulate macrophage AA turnover at higher con- 
centrations. Enkephalin had no effect on resident 
cell functions tested. There was however a stimula- 
tion of starch-elicited macrophage CAMP synthesis 
at extremely high concentrations. A similar, 
although temporary, increase in macrophage 
CAMP levels, induced by 10e6 M met-enkephalin 
has previously been demonstrated [5]. Our results 
indicate that any effects of endogenous opioid pep- 
tides on macrophage function are mediated by a 
PG-independent mechanism. It is surprising that 
we found no increase in AA turnover as enke- 
phalins have been reported to stimulate Na+ and 
Ca2+ influx [5], which might be expected to 
stimulate phospholipase activity and hence AA 
release, and endothelial cell prostacyclin formation 
[181. 
In summary our results indicate that [D-Ala2]- 
Met-enkephalin, in vitro, had no effect on macro- 
phage cyclooxygenase metabolite synthesis while 
morphine, ex vivo, induced, directly or indirectly, 
enhancement of PGE2 and TxB2 formation. 
Stimulation of PGE2 synthesis by morphine and 
the consequent inhibition of macrophage phago- 
cytic functions, together with the other immuno- 
suppressive actions of this analgesic, might 
contribute to the decreased resistance of opiate ad- 
dicts exposed to infections. 
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